What a karyotype actually shows: when it’s offered, and what it can and can’t tell you
Article produced in association with London Pregnancy Clinic
Karyotype testing has become a familiar part of fertility and pregnancy investigations. The test is older, and more specific in what it can answer, than many people realise.
Karyotyping is one of the oldest genetic tests still in routine clinical use.
The technology dates back to the late 1950s, when scientists first counted human chromosomes accurately and described conditions such as Down syndrome at the chromosomal level.
Decades later, it remains a frontline test in UK clinical practice. But the questions it answers, and the questions it doesn’t, have changed significantly with the arrival of newer genetic technologies.
The word “karyotype” now appears in a range of clinical conversations: couples investigating recurrent miscarriage, women looking into unexplained fertility difficulty, parents navigating an abnormal prenatal screening result, and adults thinking ahead about their reproductive options.
Specialist private services in the UK now offer karyotype chromosome analysis as part of broader fertility and pregnancy assessments, alongside NHS pathways.
What is less often explained is when the test is currently the right one, and where it has quietly been superseded by newer tools.
What a karyotype actually shows
A karyotype is, in effect, a photograph of all 46 chromosomes in a person’s cells, laid out in pairs and numbered.
The test uses a microscope to examine chromosomes from cultured cells: typically blood lymphocytes from an adult, amniotic fluid in mid-pregnancy testing, chorionic villus cells earlier in pregnancy, or pregnancy tissue after a miscarriage.
Karyotyping can show the total number of chromosomes, additional copies of specific ones (such as in Down syndrome, Edwards syndrome and Patau syndrome), sex chromosome variations such as Turner syndrome (45,X) and Klinefelter syndrome (47,XXY), and larger structural rearrangements including translocations, large deletions, inversions and ring chromosomes.
What it cannot see is genetic change at a smaller scale. Single-gene mutations are invisible to karyotyping. So are microdeletions and microduplications below the resolution of light microscopy, which is roughly 5 to 10 million base pairs.
The test also struggles with mosaicism if the abnormal cell line is present at low levels, and it cannot report on epigenetic changes or other functional differences.
That distinction matters: karyotyping answers a particular category of question, and other questions need different tools. NHS educational resources describe karyotype as a low-resolution genome-wide screen, superseded in many contexts by microarray but in clinical use for specific situations.
Where karyotyping is currently offered
In UK practice, karyotyping is offered in a defined set of clinical situations.
After an abnormal prenatal screening result. If a NIPT or combined screening test returns a high-chance result, or an ultrasound finds an anomaly, the NICE-recommended antenatal pathway offers chorionic villus sampling (CVS) or amniocentesis for confirmatory diagnosis. The karyotype that follows is the chromosomal confirmation step.
For couples with recurrent pregnancy loss. The Royal College of Obstetricians and Gynaecologists’ 2023 guideline on recurrent miscarriage recommends cytogenetic analysis of pregnancy tissue after three or more first-trimester losses. Parental karyotyping is then offered if the pregnancy tissue shows an unbalanced structural chromosomal abnormality, rather than as a routine first test for every couple.
In selected fertility investigations. Karyotyping may be requested for men with severe oligospermia or azoospermia, for women with primary ovarian insufficiency, and for couples with a known family history of chromosomal disorders.
For newborns and children with developmental features suggesting a chromosomal disorder. In paediatric and clinical genetics services, karyotyping continues to confirm conditions such as Down syndrome, Turner syndrome and Klinefelter syndrome.
Misconception 1: “A karyotype will explain why I keep miscarrying”
It can, sometimes, but far less often than people expect.
A UK audit of four large centres found balanced translocations in only 1.9 per cent of parents investigated for recurrent miscarriage.
Most couples who experience recurrent loss have a normal parental karyotype; the miscarriages are usually due to chromosomal abnormalities that arose in the embryo itself, not to an inherited parental rearrangement.
This is why current UK guidance, set out in the Royal College of Obstetricians and Gynaecologists’ Green-top Guideline No. 17, no longer treats parental karyotyping as the first investigation in recurrent miscarriage.
The more informative test is cytogenetic analysis of the pregnancy tissue, which typically explains the loss in over 90 per cent of samples where suitable material is available.
Parental karyotyping is then offered when the tissue analysis identifies an unbalanced structural chromosomal abnormality, in which case finding a balanced translocation in one parent has real implications for future pregnancies.
Couples in this situation often benefit from formal genetic counselling alongside the testing, to understand what each possible result would mean.
The shift in clinical practice matters: karyotyping remains useful, but for many couples the right test isn’t their own blood. It is the genetic analysis of the previous pregnancy.
Misconception 2: “A normal karyotype means there’s no genetic issue”
This is the misconception in the opposite direction.
A standard karyotype examines chromosomes at a resolution of approximately 5 to 10 million base pairs.
Genetic changes smaller than this, including most clinically meaningful microdeletions and microduplications, will not show up.
Single-gene conditions such as cystic fibrosis, sickle cell disease and fragile X syndrome are invisible to karyotyping. So is the copy-number variation associated with many developmental disorders, autism spectrum conditions and several forms of congenital heart disease.
That is why, when a karyotype returns normal but a clinical concern remains, the next test is usually chromosomal microarray (CMA) or, increasingly, whole exome or whole genome sequencing.
The NHS Genomic Medicine Service, supported by Genomics England, has significantly expanded UK access to higher-resolution genetic testing over the past five years.
A normal karyotype is reassuring at the chromosomal level. It is not a global “all clear” on every form of genetic difference.
Where karyotyping is still the right test
Despite the growth of microarray and sequencing, karyotyping remains the first-line test in specific situations.
Balanced structural rearrangements. Karyotyping detects balanced translocations and inversions that microarray cannot identify, because microarray is blind to changes that don’t add or remove genetic material.
This is the main reason karyotyping is still the test of choice for parental investigation after a recurrent miscarriage with an abnormal pregnancy tissue result.
Numerical chromosomal abnormalities. Whole-chromosome additions or losses are best detected by karyotype or QF-PCR. NIPT screens for these conditions but does not diagnose them, and a positive NIPT result is followed by a confirmatory karyotype via CVS or amniocentesis.
Sex chromosome conditions. Turner syndrome, Klinefelter syndrome and triple X are confirmed on karyotype.
Confirmation of findings from other tests. A microarray or sequencing finding is often verified with a karyotype or FISH test to identify the location and orientation of the abnormality.
What to ask before having a karyotype
For anyone considering or being offered karyotype testing, three things help:
- Be clear what question is being asked. A karyotype is the right test for some questions and not for others.
- Understand what each kind of result would mean. A “balanced translocation” finding is not a diagnosis of infertility; it indicates a risk of producing an unbalanced gamete, but many carriers go on to have healthy pregnancies.
- Ask what would come next if the result is normal. If there is still clinical concern after a normal karyotype, microarray or sequencing is usually the next step.
Karyotyping isn’t the broad genetic screening test the name sometimes implies. It is a focused test with a clear set of uses, and one that earns its place in UK clinical practice when applied to the right question.
Disclaimer
This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment. Clinical guidance referenced reflects published NHS, NICE and Genomics England information available as at May 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article. This piece was produced in association with London Pregnancy Clinic, which provided background clinical information for editorial purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
